Showing 391-400 of 3444 results for "".
Social Media Pearls and Pitfalls
https://practicaldermatology.com/topics/practice-management/social-media-pearls-and-pitfalls/18917/Despite offering new opportunities to reach patients, social media platforms also introduce a number of potential pitfalls for physicians. In this edition of Derm Insider, host Neal Bhatia discusses the complex spectrum of social media with guests Abel Torres, MD, Mark Kaufmann, MD, and Nicole DeyamStarting a Practice? Get Educated
https://practicaldermatology.com/topics/practice-management/starting-a-practice-get-educated/19109/You know your medicine, but how well do you know business topics, like human resources, accounting, marketing, staffing, and other aspects of running a practice? Consider hiring a consultant, says Todd Schlesinger, MD, FAAD.Do This Now: Be a Better Leader
https://practicaldermatology.com/topics/practice-management/do-this-now-be-a-better-leader/19111/Speaking at the Vegas Cosmetic Dermatology meeting, Todd E. Schlesinger, MD shares tips for becoming a better leader in your aesthetics practice--whether you own the practice or not. Understanding personalities and leading outside the practice walls are key.Electronic Health Records
https://practicaldermatology.com/topics/practice-management/electronic-health-records/19383/Dr. Kaufmann discusses EHRs, government incentives, and the importance of choosing a system that is right for each practice. He offers tips for residents and young physicians for choosing and using electronic health records.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Cutaneous Oncology Update: Dr. Ruiz
https://practicaldermatology.com/programs/practical-dermatology/cutaneous-oncology-update-dr-ruiz/32696/Emily Ruiz, MD, discusses the key points she covered about nonmelanoma skin cancer during "Cutaneous Oncology Update 2025" at Maui Derm 2025, as well as her poster presentation on the 40-GEP test for head and neck cutaneous squamous cell carcinomas.Cutaneous Oncology in 2024
https://practicaldermatology.com/conferences/maui-derm-2024/cutaneous-oncology-in-2024/20266/Resident Of Distinction Award-winner Banu Farabi, MD, a PGY-3 resident at New York Medical College, talks about a review she attended highlighting the latest therapeutic approaches to treating conditions such as actinic keratosis and several different types of skin cancer, as well as an overview ofResidents' Reports: A Comparison of Fractional Resurfacing Lasers
https://practicaldermatology.com/topics/general-topics/residents-reports-a-comparison-of-fractional-resurfacing-lasers/21966/Practitioners considering an investment in resurfacing lasers may benefit from this comparison of key system features.Going Off-Label
https://practicaldermatology.com/conferences/noah-worcester/going-off-label/57063/Francisca Kartono, DO, discusses her presentation, “Practical Pearls: Off-Label Topical and Systemic Strategies that Work,” from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.Improving Care Options for CTCL
https://practicaldermatology.com/videos/c-suite-chats/improving-care-options-for-ctcl/48714/Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.